Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc. is a clinical-stage precision oncology company focused on discovering and developing new cancer medicines for patients with limited treatment options. Its pipeline includes a JAK2V617F program aimed at myeloproliferative neoplasms such as myelofibrosis, polycythemia vera, and essential thrombocythemia; a KAT6A program being developed for advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates for myelofibrosis and essential thrombocythemia. The company also has a collaboration with AbCellera Biologics to support the discovery, development, and commercialization of degrader antibody conjugates. Incorporated in 2016, Prelude Therapeutics is based in Wilmington, Delaware, and its common stock trades on the NASDAQ under the symbol PRLD.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PRLD
|
$5.48
|
12.9% Upside
|
Fair
|
$9.20
|
89.7% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
3.6x
|
21.6x
|
499.5 M
|
350 M
|
3.5%
|
21.4%
|
-0.3
|
55.0%
|
